You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Claims for Patent: 10,912,772

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,912,772

Title:	Opioid formulations
Abstract:	A depot precursor formulation comprising:
Inventor(s):	Tiberg Fredrik, Harwigsson Ian, Johnsson Markus
Assignee:	Camurus AB
Application Number:	US16882186
Patent Claims:	1. A method of administering an opioid maintenance treatment to a patient , the method comprising administering a composition to the patient from a pre-filled syringe containing the composition , wherein the composition is administered subcutaneously to the patient once-weekly and comprisesabout 5% by weight of buprenorphine;about 10% by weight of ethanol;about 42% by weight of a phosphatidylcholine; andabout 42% by weight of glycerol dioleate.2. The method of claim 1 , wherein the patient suffers from an opioid dependency.3. The method of claim 2 , wherein the patient suffers from opioid withdrawal.4. The method of claim 1 , wherein administering the opioid maintenance treatment treats pain in the patient.5. The method of claim 1 , wherein the composition comprises 3 to 40 mg of buprenorphine.6. The method of claim 1 , wherein the patient is receiving or has previously received an oral dosage form comprising buprenorphine.7. The method of claim 6 , wherein the oral dosage form is sublingual.8. The method of claim 1 , wherein the composition claim 1 , after contact with an aqueous fluid claim 1 , forms a liquid crystalline phase structure.9. The method of claim 8 , wherein the liquid crystalline phase structure is a non-lamellar crystalline phase structure.10. The method of claim 1 , wherein claim 1 , at steady state plasma concentrations claim 1 , the Cmin and Cmax of buprenorphine in the patient is between about 0.4 ng/mL and 10 ng/mL.11. The method of claim 1 , wherein the Cmin and Cmax of buprenorphine in the patient is between about 0.4 ng/mL and 10 ng/mL for at least a week after administration.12. The method of claim 1 , wherein the blood plasma concentration of buprenorphine in the patient is at least 0.2 ng/mL for at least a week.13. A method of administering an opioid maintenance treatment to a patient claim 1 , the method comprising administering a composition to the patient from a pre-filled syringe containing the composition claim 1 , wherein the composition is administered subcutaneously to the patient once-weekly and comprisesabout 5.29% by weight of buprenorphine;about 10% by weight of ethanol;about 42.36% by weight of a phosphatidylcholine; andabout 42.36% by weight of glycerol dioleate.14. The method of claim 13 , wherein the patient suffers from an opioid dependency.15. The method of claim 14 , wherein the patient suffers from opioid withdrawal.16. The method of claim 13 , wherein the composition comprises 3 to 40 mg of buprenorphine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.